Literature DB >> 2461668

The mechanism of tachykinin-induced bronchoconstriction in the rat.

G F Joos1, R A Pauwels, M E van der Straeten.   

Abstract

The mammalian tachykinins substance P (SP) and neurokinin A (NKA) are known to be present in sensory airway nerves of animals and humans. We studied the effect of mammalian and nonmammalian tachykinins on the conducting airways of anesthetized, mechanically ventilated Fisher 344 rats. Dose-dependent increases in lung resistance and decreases in dynamic compliance occurred after the intravenous administration of eledoisin (E), kassinin (K), NKA, and SP. E, K, and NKA were more potent bronchoconstrictors than was SP. Neurokinin B (NKB) caused a similar decrease in dynamic compliance, but had no effect on lung resistance. This order of potency suggests a predominance of NK-2 receptors in the rat airways. Both atropine and the 5-hydroxytryptamine antagonist methysergide largely reduced the bronchoconstriction induced by E and SP. Vagotomy did not change this reaction, whereas pretreatment with the ganglion blocker hexamethonium slightly enhanced the bronchoconstrictor action of E and SP. Sodium cromoglycate and nedocromil sodium, 2 drugs that can inhibit mediator release from inflammatory cells, significantly reduced the bronchoconstrictor action of NKA. Ketotifen, an antihistamine with mast-cell-stabilizing properties, significantly reduced the bronchoconstriction induced by E, whereas the H1-receptor antagonist clemastine had no effect. We conclude that tachykinins cause bronchoconstriction in rats largely by an indirect mechanism, involving both acetylcholine and 5-hydroxytryptamine. We suggest that tachykinins cause bronchoconstriction by stimulation of postganglionic vagal nerve endings and mast cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2461668     DOI: 10.1164/ajrccm/137.5.1038

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  11 in total

Review 1.  Long-term drug treatment of asthma in children.

Authors:  K F Kerrebijn
Journal:  Lung       Date:  1990       Impact factor: 2.584

2.  Effects of hyperosmolarity on human isolated central airways.

Authors:  R C Jongejan; J C de Jongste; R C Raatgeep; T Stijnen; I L Bonta; K F Kerrebijn
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

Review 3.  Genetic factors controlling airway responsiveness.

Authors:  R A Pauwels
Journal:  Clin Rev Allergy       Date:  1989

4.  Effect of nedocromil sodium on bronchoconstriction induced by adenosine and tachykinins.

Authors:  R Pauwels; G Joos; M Van der Straeten
Journal:  Drugs       Date:  1989       Impact factor: 9.546

5.  Capsaicin and sensory neuropeptide stimulation of goblet cell secretion in guinea-pig trachea.

Authors:  H P Kuo; J A Rohde; K Tokuyama; P J Barnes; D F Rogers
Journal:  J Physiol       Date:  1990-12       Impact factor: 5.182

6.  Effect of nedocromil sodium on the bronchoconstrictor effect of neurokinin A in asthmatics.

Authors:  G F Joos; R A Pauwels; M E Van der Straeten
Journal:  Drugs       Date:  1989       Impact factor: 9.546

7.  Airway hyperresponsiveness to bradykinin induced by allergen challenge in actively sensitised Brown Norway rats.

Authors:  K M Ellis; C Cannet; L Mazzoni; J R Fozard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-01-15       Impact factor: 3.000

8.  Electrophysiological effects of tachykinins and capsaicin on guinea-pig bronchial parasympathetic ganglion neurones.

Authors:  A C Myers; B J Undem
Journal:  J Physiol       Date:  1993-10       Impact factor: 5.182

9.  Poly-L-arginine-mediated release of acetylcholine from parasympathetic nerves in rat and guinea-pig airways.

Authors:  D Spina; R G Goldie
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

10.  Characterization of NK1 and NK2 tachykinin receptors in guinea-pig and rat bronchopulmonary and vascular systems.

Authors:  A Floch; V Fardin; I Cavero
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.